Repros Therapeutics Inc. (NASDAQ:RPRX) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 19.26M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.
Repros Therapeutics Inc. (NASDAQ:RPRX) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For RPRX, the company currently has 4.68 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 5.87 million in total assets, balanced by 6.18 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Repros Therapeutics Inc. (RPRX) saw -1.98 million in free cash flow last quarter, representing a quarterly net change in cash of 533,000. Perhaps most importantly where cash movements are concerned, the company saw about -1.98 million in net operating cash flow.
Repros Therapeutics Inc. (NASDAQ:RPRX) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the RPRX saw sales decline by 0.00.
But what about the bottom line? After all, that’s what really matters in the end. Repros Therapeutics Inc. (RPRX) is intriguing when broken down to its core data. The cost of selling goods last quarter was 1,000, yielding a gross basic income of -1,000 . For shareholders, given the total diluted outstanding shares of 28.4 million, this means overall earnings per share of -0.08.
Is Repros Therapeutics Inc. (NASDAQ:RPRX) Valuation Attractive
One should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Repros Therapeutics Inc..